Product Details
Synonym
CD19, B4, CVID3, MGC12802
Source
Cynomolgus / Rhesus macaque CD19 (20-292), His Tag (CD9-C5221) is expressed from human 293 cells (HEK293). It contains AA Pro 20 - Lys 292 (Accession # F7F486-1).
Request for sequenceMolecular Characterization

Other Tags and Version Biotin & Other Labeled Version
This protein carries a polyhistidine tag at the C-terminus.
The protein has a calculated MW of 32.1 kDa. The protein migrates as 45-65 kDa when calibrated against Star Ribbon Pre-stained Protein Marker under reducing (R) condition (SDS-PAGE) due to glycosylation.
Endotoxin
Less than 1.0 EU per μg by the LAL method / rFC method.
Purity
>90% as determined by SDS-PAGE.
Formulation
Lyophilized from 0.22 μm filtered solution in PBS, pH7.4 with trehalose as protectant.
Contact us for customized product form or formulation.
Reconstitution
Please see Certificate of Analysis for specific instructions.
For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.
Storage
For long term storage, the product should be stored at lyophilized state at -20°C or lower.
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
- -20°C to -70°C for 12 months in lyophilized state;
- -70°C for 3 months under sterile conditions after reconstitution.
ACRO Quality Management System
Customers Also Viewed
Performance Data
SDS-PAGE

Cynomolgus / Rhesus macaque CD19 (20-292), His Tag on SDS-PAGE under reducing (R) condition. The gel was stained with Coomassie Blue. The purity of the protein is greater than 90% (With Star Ribbon Pre-stained Protein Marker).
Bioactivity-ELISA

Immobilized Anti-CD19 Antibody at 0.1% can bind Cynomolgus / Rhesus macaque CD19 (20-292), His Tag (Cat. No. CD9-C5221) with a linear range of 0.001-0.078 μg/mL (Routinely tested).
Protocol
Customer Reviews Writing Reviews

Background
Recent Advances
- English Name:
B-lymphocyte antigen CD19
- Category:
- Approved Drugs:
12 Details
- Drugs in Clinical Trials:
310 Details
- Highest Development Stage:
NDA/BLA
[North America]: +1 800-810-0816
[Switzerland]: +41 800 040 012
[Asia & Pacific]: +86 400-682-2521
















